Latest News and Press Releases

Positive IW-6463 translational pharmacology study in healthy elderly subjects showed significant improvements in multiple measures associated with age-related cognitive decline and neurodegenerative...

CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase...

CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases,...

-  IW-6463 and olinciguat top line clinical study results remain on track for late summer and late Q3 2020, respectively   - -  Completed $24 million equity private placement to accelerate clinical...

 - Additional capital to accelerate clinical development of IW-6463 in two CNS indications and olinciguat for sickle cell disease - - IW-6463 translational pharmacology and olinciguat STRONG Phase...

CAMBRIDGE, Mass., July 17, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases,...

-  CNS focused investor event to precede clinical study results  –  -  IW-6463 translational pharmacology study subject dosing complete; topline data expected late summer 2020  - CAMBRIDGE,...

– Closed enrollment for olinciguat Phase 2 STRONG SCD study for sickle cell disease; topline data readout expected Q3 2020 –       – Closed enrollment for IW-6463 translational pharmacology...

– Results in 110 subjects demonstrate favorable safety, CNS pharmacokinetics, and evidence of target engagement – – Study underway in elderly subjects to further assess cerebral blood flow and...

– Management to review the Company's sGC clinical pipeline programs: praliciguat for diabetic nephropathy, olinciguat for sickle cell disease, and IW-6463 for neurodegenerative diseases – CAMBRIDGE,...